Biotech
Sponsored
Bulls N' Bears
Hydration rehydrates share price with non-US asset sale
This week’s Bulls N’ Bears Runner of the Week is … Hydration Pharmaceuticals. The company sold its non-US assets for a sum five times its market capitalisation.
- by Craig Nolan
Latest
It introduced Ozempic to the world. Now it must remake itself
Danish drugmaker Novo Nordisk has eclipsed French luxury group LVMH to become Europe’s most valuable company – thanks to demand for diabetes and weight-loss drugs.
- by Eshe Nelson
The artificial heart set to transform medicine – and the Aussie who invented it
Biomedical engineer Daniel Timms lost his father to heart disease, but their kitchen-top tests helped him hone a radical idea.
- by Amanda Hooton
Magazine
Good Weekend
The April 20 Edition
The Aus-designed artificial heart set to revolutionise medicine | Preppers go mainstream | A sperm donor’s message to his progeny
Opinion
Health
Our track record in medical innovation can only be maintained with funding support
Australian researchers are responsible for a series of globally significant medical inventions and innovations.
- by The Herald's View
Future of medical research in doubt as question mark lingers over $45 million funding
The future of a government funding program which has assisted teams developing artificial hearts and turning spider venom into drug therapies is in doubt.
- by Mary Ward
Exclusive
Healthcare
His dad was dying. So Daniel built a world-first artificial heart – with pipes and magnets
Australia will spend $50 million building the world’s first long-term artificial heart, after the original prototype was built with pieces bought from Bunnings.
- by Sherryn Groch
Failed drug trial overshadows CSL’s bumper profits
Investors have punished the company’s share price for the second day in a row – despite it booking revenue of $12.3 billion for the half-year to December 31.
- by David Swan
Health behemoth CSL sheds $7b in value after heart drug fails trial
Shares in the blood plasma treatments maker were trading nearly 5 per cent lower following the results.
- by Millie Muroi
Exclusive
Education
Australia underspends on this key area. It may put national security at risk
Australia’s underinvestment in research is becoming a national security issue, some university heads argue, ahead of a landmark review and the AUKUS deal.
- by Sherryn Groch and Daniella White
Growing frustration for seaweed farmer at Labor’s ‘incredibly slow’ action to cut cow methane
After rubbing shoulders in Singapore with Prince William, Sea Forest founder Sam Elsom is eager for the Albanese government to back his plan to help save the planet.
- by Chris Barrett
Original URL: https://www.theage.com.au/topic/biotechnology-5v0